Medical Pharmacology: Cancer Chemotherapy Drugs: Anti-Metabolites Practice Questions

Clofarabine (Clolar), a 2-chloro analog of cladribine:
1. Exhibits enhanced ability
2. Demonstrates increased uptake
3. Exhibits enhanced phosphorylation
4. A & C
5. B & C
6. A, B & C
Clofarabine (Clolar) has been approved for childhood acute lymphocytic leukemia following failure of two earlier therapeutic approaches.
1. True
2. False
Clofarabine pharmacology:
1. Clofarabine triphosphate, the active form, exhibits a half-life of about one day
2. Following incorporation into DNA, Clofarabine triphosphate induces chain termination.
3. Both
4. Neither
Clofarabine clinical toxicity/toxicities:
1. Myelosuppression
2. Hypotension, pulmonary edema and organ dysfunction consistent with both cytokine release and capillary leak syndrome.
3. Both
4. Neither
Nelarabine (Arranon) is a single guanine nucleotide in clinical use.
1. True
2. False
Nelarabine therapeutic activity/activities:
1. Hepatocellular carcinoma
2. Acute T-cell leukemia
3. T-cell lymphoblastic leukemia
4. A & B
5. B & C
6. A, B & C
Nelarabine mechanism of action: stopping DNA synthesis after incorporation into DNA.
1. True
2. False
Nelarabine side effect/side effects:
1. Myelosuppression
2. Neurological affects
3. Both
4. Neither
Pentostatin (Nipent):
1. Inhibits adenosine deaminase
2. Administration of Pentostatin results in increased intracellular adenosine and deoxyadenosine nucleotides, blocking DNA synthesis by inhibiting ribonucleotide reductase.
3. Both
4. Neither
Pentostatin administration may be used to induce complete remission and partial responses in hairy cell leukemia (cladribine is now more commonly used).
1. True
2. False